By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ZLB Behring L.L.C. 

A CSL Company
1020 First Avenue
King of Prussia  Pennsylvania  19406  U.S.A.
Phone: 610-878-4000 Fax: 610-878-4009



Company News
ZLB Behring Foundation Calls For Grant Applications 11/16/2006 11:58:35 AM
ZLB Behring Names Robert D. Lefebvre, Ronan W. Gannon, Garrett E. Bergman, M.D., To Top U.S. Management Posts 9/18/2006 10:34:59 AM
ZLB Behring Release: VIRTUE, Largest Clinical Trial Of Subcutaneous Immunoglobulin Therapy, Opens To Primary Immunodeficiency Patients Across The U.S. 9/12/2006 12:07:23 PM
ZLB Behring Foundation Calls For Grant Applications 6/22/2006 2:01:13 PM
ZLB Behring Foundation Awards Grants To Benefit Bleeding Disorders Community 6/5/2006 2:42:05 PM
ZLB Behring Release: New International Study Group Seeks To Set Standards For Prevention, Treatment Of Bleeding In Patients With von Willebrand Disease (VWD) 5/23/2006 11:17:36 AM
ZLB Behring Release: First International Census On Von Willebrand Disease (VWD): 77 Percent Of Patients With Severe Type 3 VWD Experience Significant Bleeding-Related Events 5/22/2006 11:26:24 AM
State-Of-The-Art ZLB Behring Plant Licensed By The FDA 4/18/2006 2:33:41 PM
ZLB Behring Release: Study Finds Treatment With C1-Inhibitor Concentrate Relieves Abdominal Pain In Hereditary Angioedema Patients 3/6/2006 11:33:48 AM
ZLB Behring Release: Study Shows Individual Replacement Therapy With C1-Inhibitor Concentrate Reduces Life-Threatening Hereditary Angioedema Attacks Compared With Current Treatment Of Choice 3/6/2006 11:13:50 AM